ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 467

The Prevalence and Clinical Features of Co-Occurring Autoimmunity in Children with Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry

Ohoud AlAhmed1, Vidya Sivaraman2, Melissa Moore-Clingenpeel3, Stacy P. Ardoin4 and Sharon Bout-Tabaku5, 1Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, 2Pediatrics, The Ohio State University, COLUMBUS, OH, 3Research, Nationwide Children's Hospital, Dublin, OH, 4Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, 5Rheumatology, Nationwide Children's Hospital, Columbus, OH

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: autoimmune diseases and pediatrics, Co-morbidities, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The co-occurrence of autoimmune disorders (AI) with systemic lupus erythematosus (SLE) in adults is associated with poor disease outcomes. We describe the co-occurrence of other AI in children with SLE (cSLE) and evaluate the relationship between comorbid AI and lupus disease outcomes using the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry.

Methods:

The CARRA Legacy Registry is a multicenter prospective, observational, longitudinal database of children with defined rheumatic conditions including SLE. Subjects were enrolled from May 2010 through July 2014 at any time during their disease course and data were collected at 6-month interval follow up visits from 60 clinical sites in the US and Canada. 1285 subjects met the American College of Rheumatology (ACR) 1997 criteria for SLE. We defined comorbid AI as the presence of any of the following diseases: Hashimoto’s thyroiditis, Celiac disease and type 1 diabetes mellitus. Disease outcomes were assessed by measures of disease activity and impact on quality of life (QoL). Comparisons by AI status were made using chi-square, Fisher’s exact, two-sample t-tests, Wilcoxon rank sum tests, and mixed effects models as appropriate.

Results:

Data on the co-occurrence of AI were available in 388 (30%), unknown in 31 (2%), and missing in 866 (67%) at the baseline visit. The prevalence of comorbid AI was 20% (n=79). When comparing subjects with AI (n=79) to those without AI (n=309), subjects with AI were significantly younger at onset of lupus and had more 1st degree relatives with AI (Table 1). Subjects without AI had significantly more renal disease at the time of enrollment. During follow up visits, the average Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score over time was significantly lower among subjects without AI. There were no significant differences over time in the Physician Global Assessment (PGA) level of disease activity by comorbid AI. Overall, there were no significant differences in the QoL measures or their trajectory over time based on the presence of comorbid AI (Figure 1).

Conclusion:

Among children with SLE, the co-occurrence of another AI is associated with younger age at presentation, but is not associated with poor disease outcomes. Out study was limited by missing data on our variables of interest. Future plans include validating our results using the new prospectively collected CARRA Registry that has more complete data on comorbid AI and lupus disease outcomes.

 

Table 1: Baseline comparison by comorbid autoimmune disorders

 

All subjects with available data on AI (n = 388)

Without AI

(n = 309)

With AI

(n = 79)

p-value*

 

N

%

N

%

N

%

 

Ethnicity

 

 

 

 

0.750

Hispanic

103

26.55

79

26

22

28

 

Race

 

 

 

 

0.4434

White

216

55.67

172

56

45

57

 

African American

106

27.32

82

27

23

29

 

Asian

33

8.51

28

9

5

6

 

Other

7

1.8

5

2

2

3

 

Sex

 

 

 

 

0.2475

Female

308

79.38

248

80

59

75

 

Insurance

 

 

 

 

0.4457

Yes

364

93.81

287

93

78

99

 

Smoking

 

 

 

 

>0.9999

No

262

67.53

215

69

50

63

 

AI in 1st degree relative

 

 

 

 

 

 

0.0069

No

214

55.15

181

59

32

41

 

Yes

146

37.63

108

35

39

49

 

Age at primary disease onset (n=383) mean, sd

11.41

3.802

11.60

3.778

10.61

4.56

0.0406

Time in years to SLE Dx (n=382), median (IQR)

0

(0,1)

0

(0,1)

0

(0,1)

0.9670

Renal disease

167

43.04

140

46

26

33

0.0357

SLEDAI (n=352), median (IQR)

4

(0,8)

4

(0,8)

2

(0,8)

0.1834

Numbers of missing data: Ethnicity 1 (0.26%), Race 19 (4.9%), Insurance 14 (3.61%), Smoking 122 (31.44%), AI in 1st degree relative 28 (7.22%).

AI = autoimmune disorders

*after excluding missing data

 


Disclosure: O. AlAhmed, None; V. Sivaraman, None; M. Moore-Clingenpeel, None; S. P. Ardoin, None; S. Bout-Tabaku, None.

To cite this abstract in AMA style:

AlAhmed O, Sivaraman V, Moore-Clingenpeel M, Ardoin SP, Bout-Tabaku S. The Prevalence and Clinical Features of Co-Occurring Autoimmunity in Children with Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-prevalence-and-clinical-features-of-co-occurring-autoimmunity-in-children-with-systemic-lupus-erythematosus-the-childhood-arthritis-and-rheumatology-research-alliance-carra-legacy-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-prevalence-and-clinical-features-of-co-occurring-autoimmunity-in-children-with-systemic-lupus-erythematosus-the-childhood-arthritis-and-rheumatology-research-alliance-carra-legacy-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology